Use Cases
Areas of study. This hub organizes the topic into a starting point, core reading, and deeper reference material so mobile readers and search systems can understand the page pathway quickly.
Get oriented first
Begin with the plain-language framing before reading narrower claims or legal and safety details.
Read the central articles
Use the core set to understand the topic before moving into edge cases and supporting references.
Education, not instruction
This section does not provide medical, dosing, sourcing, purchasing, or legal advice.
A neutral overview of microdosing use-case research: the conditions it covers, how evidence is ordered by quality, and its core question — compound versus belief.
Microdosing may affect sleep indirectly via anxiety and stress, but there's no direct controlled evidence of a sleep benefit, and late doses can disrupt sleep.
Microdosing for Addiction: The Full-Dose Signal and the Microdose GapPsilocybin shows notable full-dose results for alcohol and smoking cessation, while microdosing evidence stays observational — where the stronger evidence sits.
Microdosing for ADHD and Focus: What Research Actually ShowsMicrodosing for ADHD and focus is widely reported but variable — some improve, some worsen. Why response differs so much here, and why self-observation matters.
Anxiety is the most consistently reported microdosing use case. What observational studies, mechanisms, and full-dose trials do and don't establish about it.
Microdosing for Chronic Pain: What the Research Actually SuggestsMicrodosing for chronic pain is early-stage: interest centers on fibromyalgia and central sensitisation via 5-HT2A mechanisms, but evidence stays preliminary.
Microdosing for Creativity: What Studies Actually ShowCreativity is the most reported microdosing benefit, but controlled evidence is weak: studies hint at cognitive-flexibility gains; broader claims stay anecdotal.
Microdosing for Depression: What the Evidence Supports, and What It Doesn'tDepression is among the most reported use cases and has the strongest full-dose trials. What transfers to microdosing, what doesn't, and why SSRIs complicate it.
Microdosing for OCD: What Research Actually SuggestsOCD has a strong serotonergic rationale and an early psilocybin study showing symptom reductions, but microdosing-specific evidence remains minimal and preliminary.
Microdosing for PTSD: What Research Actually SuggestsPTSD microdosing is early-stage: fear-extinction pathways give a plausible rationale, but evidence is observational and trauma resurfacing poses real risks.
Microdosing for Stress and Burnout: What Research Actually SuggestsStress and burnout reports mirror anxiety findings on reduced reactivity, but evidence stays observational, placebo-sensitive, and limited by structural causes.
Psilocybin for Cluster Headaches: Real Evidence, but Not MicrodosingCluster-headache and migraine research uses periodic perceptible doses, not daily microdosing. Where the real evidence sits and why the protocols differ.
Psilocybin for End-of-Life Distress: Strong Evidence, but Full-DoseJohns Hopkins and NYU trials found large, durable reductions in existential distress after single supervised full doses — a different intervention than microdosing.